Next 10 |
2024-04-18 17:13:33 ET Related stories Grand Theft Auto publisher Take-Two Interactive to lay off 5% of workforce Equifax Earnings: Underwhelming Performance, Not Worth The Investment Tenet Healthcare: Shrinking To Grow Wabtec: Railing Along To Fresh Highs ...
2024-04-18 12:15:04 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for ARGX on April 18, 2024 10:01AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $363.76 at issue of the analyst recommendation. The overall analyst consensu...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...
2024-04-10 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-04-10 06:50:33 ET Summary Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock re...
2024-04-04 02:12:07 ET Summary Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial hea...
2024-03-30 19:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ...
2024-03-26 16:15:02 ET Wells Fargo analyst issues MARKET OUTPERFORM recommendation for ARGX on March 26, 2024 03:01PM ET. The previous analyst recommendation was Market Outperform. ARGX was trading at $398.96 at issue of the analyst recommendation. The overall analyst co...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 1...
News, Short Squeeze, Breakout and More Instantly...
argenx SE Company Name:
ARGX Stock Symbol:
NASDAQ Market:
2024-04-18 12:15:04 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for ARGX on April 18, 2024 10:01AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $363.76 at issue of the analyst recommendation. The overall analyst consensu...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patien...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...